Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Ig NexGen 10% in ITP
NCT00362349Phase 3Completed
- Sponsor
- CSL Limited
- Start
- Jun 2007
- Primary completion
- Oct 2008
- Modality
- Recombinant Proteins and Enzymes
- Countries
- 1
01
Overview
Phase 3, open-label, single-arm trial of intravenous immunoglobulin G in immune thrombocytopenia (ITP), sponsored by CSL Limited. Primary endpoint: Efficacy at 90 days. Started Jun 2007; status: completed.
02
Drugs
intravenous immunoglobulin G
03
Conditions
immune thrombocytopenia (ITP)
Beyond the preview
Go deeper on NCT00362349.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT00362349.